about
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional studyUnmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseDose of prophylactic platelet transfusions and prevention of hemorrhageNeonatal lupus erythematosus with microvascular hemolysis.Management of bleeding disorders in children.Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone.Treatment options for bleeding episodes in patients undergoing immune tolerance therapy.Blood transfusion support in pediatric cardiovascular surgery.AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.Gene therapy for bleeding disorders.Guidelines for assessing appropriateness of pediatric transfusion.Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.Modern management of haemophilic arthropathy.Utility of computed tomography of the head following head trauma in boys with haemophilia.Incidence of bleeding complications in pediatric patients with type 1 von Willebrand disease undergoing adenotonsillar procedures.Update on hemoglobinopathies.What's new in transfusion medicine?Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.Alloimmunization to platelets in heavily transfused patients with sickle cell disease.Pediatric hematology.Complex regional pain syndrome in pediatric patients with severe factor VIII deficiency.CD8(+) T-cell responses to adeno-associated virus capsid in humans.Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States.Emerging and receding risks of therapeutic regimens for haemophilia.Low recovery in vivo of highly purified factor VIII in patients with hemophilia.Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.The clinical management of hemophilia and head trauma: a survey of current clinical practice among pediatric hematology/oncology physicians.Therapeutic choices in the current millennium: hemophilia workshop highlights.Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant.A prospective observational study of IVC filters in pediatric patients.Distinguished Career Award of the American Society of Pediatric Hematology/Oncology for 2000.The presurgical management with erythrocytapheresis of a patient with a high-oxygen-affinity, unstable Hb variant (Hb Bryn Mawr).Splenectomy in mild hereditary spherocytosis: is it worth the risk?Sickle cell anemia and cholelithiasis.Use of acetyl chloride/methanol for assumed selective methylation of plasma nonesterified fatty acids results in significant methylation of esterified fatty acids.Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation*May–Thurner syndrome (iliac vein compression) and thrombosis in adolescents
P50
Q24685850-645A355F-AC91-494E-9B12-5F49E9EE36AAQ28270195-7DD7540E-4954-4011-A33E-E55A451FB72FQ28293136-F81941EF-BFC5-4A01-9819-2DA0E7957DCDQ29619095-238F072A-027C-447F-83C3-CC29E2F2062DQ30496886-4AA0A3F8-5007-4B9B-BA9E-1E7242968649Q33333756-9AD4C679-F56A-4213-B1B5-788B90206607Q33369328-6B2754EE-788A-426D-9C9A-85AE51C50D66Q33492561-AE8DA54A-CB3D-4F71-BCDB-1439EE019DC2Q33794095-1EB71AB1-5FDD-4D73-B533-9964BEF84F16Q33867785-CEF62730-172F-4EDB-AE90-03E056F5F06AQ34168942-E68FB93F-0A90-4C1D-A4AF-067C73989C12Q34977563-CEAD6B52-9720-434D-A211-705911E41DAFQ34991606-6F26E8A2-0E6C-4836-BA06-B79057E295E4Q36443121-40EBD1BF-D2CB-4273-A7B7-038D8CE61CBBQ36753030-AD485DC8-098F-4D0A-BE87-9CC920E4B8D8Q36945957-1F80B731-D858-449C-AF43-659392070AC8Q37459927-837C83FA-AF48-46E8-B0B9-D5890D6B2D28Q40153496-6F88F8B5-254E-48C3-B726-FBC559542C58Q40998004-235F84D9-6E01-40EB-B8A9-B238B360DAACQ41722852-245C5CEE-8300-44BD-A2DC-30A01445FFA1Q41930008-F1B7AEC6-6915-4FF3-8ABA-E8A10D02224DQ43578819-7CC4564A-B90D-4B39-B98D-433A7973C540Q43922443-E49AAD48-E998-4AF7-8C8D-477A38CD86CCQ45406111-8C69ABDC-DD68-4398-8272-FFD4400C1D22Q45859498-02CC0CB5-43D3-42ED-A461-0EDF540B71F2Q45865299-B2CBC746-5971-4513-9ABC-66C1EE8FFD57Q45878744-53CCA1BB-5735-4637-81E7-427CBBF3F7B0Q45879523-C16B988D-6592-4CC6-8D1B-DB7D570F4183Q45881352-238C220B-55C7-40FA-A2DC-6D599ED12C3AQ45885789-4BD5F565-5864-4027-A715-411008EA8C62Q45886324-EC3A5761-2A8E-4E2A-8DAA-3600A2EA9F8AQ45924225-6B8B7D54-36C9-476D-AB17-C3A1AFAADAB0Q47629885-7F28D19D-0A0F-4507-AF20-11901036F677Q48372594-6B03BDD7-C8C3-452E-9054-3B3128F37920Q50156052-2A7B2992-BB78-41C1-9D3E-C4ECDBCED7DBQ50169223-F9BC7C9A-91FC-4161-AE5A-0BBB34E6374EQ50173313-D6F9C79D-BC72-45C6-9CE9-196D495B0E66Q51601092-0DF3D49E-46C7-4D7B-8DA8-FE655ADD8486Q57911145-5F5C06D1-36CE-4926-B99F-C2BFD0ED9981Q62754727-AFCCC3A7-9974-4FEF-8115-0800895AB458
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Catherine Manno
@ast
Catherine Manno
@en
Catherine Manno
@es
Catherine Manno
@nl
Catherine Manno
@sl
type
label
Catherine Manno
@ast
Catherine Manno
@en
Catherine Manno
@es
Catherine Manno
@nl
Catherine Manno
@sl
prefLabel
Catherine Manno
@ast
Catherine Manno
@en
Catherine Manno
@es
Catherine Manno
@nl
Catherine Manno
@sl
P214
P244
P106
P21
P214
P244
no2003076643
P31
P496
0000-0001-8029-0391
P735
P7859
lccn-no2003076643